A sleep medication monitoring checklist tracks dosage, side effects, interactions, and response over time so a prescriber can judge whether a drug is helping or harming someone with Alzheimer's disease. The checklist matters because sedatives behave differently in people with dementia than in other older adults, and the wrong drug can raise fall and mortality risk rather than fix sleep. Caregivers who monitor consistently catch problems early: new confusion, daytime grogginess, or a fall in the days after a dose change. The sections below cover which drugs have evidence behind them, which carry warnings, what to track day to day, and what to bring to a medication review.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which sleep medications actually have evidence in Alzheimer's disease?
- Why antipsychotics carry a boxed warning for sleep problems in dementia
- Should melatonin or other common aids be on the list?
- What belongs on the daily monitoring checklist
- When to call the prescriber right away
Which sleep medications actually have evidence in Alzheimer's disease?
Suvorexant (brand name Belsomra) is the only insomnia drug with FDA approval specific to Alzheimer's disease. The FDA expanded its label on February 3, 2020, to cover people with mild-to-moderate Alzheimer's, based on a phase 3 trial of 285 patients. In that four-week trial, people taking suvorexant gained 28.2 more minutes of total sleep than those on placebo and fell asleep with less time spent awake after initially drifting off.
Side effects were more common on the drug: 22.5% of suvorexant patients had an adverse event, most often mild to moderate daytime sleepiness, versus 16.1% on placebo, according to the AASM's summary of the trial. That approval does not extend to other common sleep drugs. Benzodiazepines and "Z-drug" hypnotics such as zolpidem, eszopiclone, and zaleplon are not approved for dementia-related insomnia, and the 2023 American Geriatrics Society Beers Criteria lists them as drugs older adults should avoid, citing higher risk of cognitive impairment, delirium, falls, and fractures — with dementia patients especially vulnerable, per the Beers Criteria summary.
Why antipsychotics carry a boxed warning for sleep problems in dementia
Antipsychotic drugs are sometimes used off-label to settle agitation or nighttime restlessness in dementia, but none of them is approved for that use. The FDA ordered a boxed warning — its strongest safety alert — in April 2005 after pooling 17 placebo-controlled trials of olanzapine, aripiprazole, risperidone, and quetiapine in 5,106 elderly dementia patients. Mortality was 1.6 to 1.7 times higher than placebo, mostly from cardiovascular events or pneumonia, according to the FDA's 2005 Public Health Advisory.
The FDA extended the same boxed warning to older antipsychotics, including haloperidol and perphenazine, in June 2008. That decision followed two 2007 Canadian studies showing comparable or higher mortality with older antipsychotics than with the newer ones already under warning, as described in the FDA's 2008 notice. For a monitoring checklist, this means any antipsychotic prescribed for sleep or nighttime behavior should be flagged for closer tracking than a standard sleep aid: changes in heart rhythm, breathing, swallowing difficulty, and signs of infection all warrant a prompt call to the prescriber.
Should melatonin or other common aids be on the list?
Melatonin is widely used because it is sold without a prescription, but the evidence for it in Alzheimer's disease is inconsistent. A 2020 meta-analysis found little or no effect on sleep or cognition in people with Alzheimer's and sleep disturbance, while a 2021 meta-analysis found cognitive benefit in only some patients — a mixed picture rather than a clear recommendation, summarized by the Alzheimer's Drug Discovery Foundation. The American Academy of Sleep Medicine's 2015 clinical practice guideline strongly recommends against using sleep-promoting medications, and weakly recommends against melatonin, for circadian rhythm sleep-wake disturbances in older adults with dementia.
The guideline cites fall risk and no clear benefit to neurologic function as the reasons, per the AASM/Journal of Clinical Sleep Medicine guideline. Because melatonin is available over the counter, it is easy for a caregiver to start it without telling the prescriber. Any over-the-counter sleep aid belongs on the same monitoring list as a prescription drug, tracked for the same side effects and logged at the next medication review.
What belongs on the daily monitoring checklist
A caregiver tracking a sleep medication should log a consistent set of items every day, not just when something seems wrong. Clinical guidance from the Alzheimer Society of Canada and the Mayo Clinic holds that sleep medication should be a last resort after non-drug measures, and that it needs ongoing oversight from a prescriber experienced with dementia care, per Mayo Clinic's guidance.
Track these items daily: Bring this log to every medication review, along with a full list of what else the person takes. A review should specifically check for other drugs that disrupt sleep, including cholinesterase inhibitors and some antidepressants, which can cause insomnia if taken too late in the day, according to Mayo Clinic. A log that shows a new symptom starting the same week as a new drug — prescription or not — is the clearest signal a prescriber can act on.
- Time the dose was given and whether it was taken as prescribed
- Time to fall asleep and total hours slept, as best as can be observed
- Nighttime awakenings, wandering, or confusion episodes
- Daytime drowsiness, grogginess, or unusual sleepiness
- New unsteadiness, stumbling, or a fall
When to call the prescriber right away
Some findings on the checklist warrant a same-day call rather than waiting for the next scheduled visit. A fall, a sudden increase in confusion, difficulty swallowing, chest pain, or signs of infection such as fever or a new cough all fall into this category, given the cardiovascular and pneumonia risks tied to antipsychotic use in dementia noted in the FDA's warnings.
Excessive daytime sleepiness that interferes with eating, walking, or basic conversation also warrants a call rather than watchful waiting, since it was the most common adverse event reported in the suvorexant trial and can compound fall risk on its own. A caregiver does not need to diagnose the cause — reporting the symptom, the timing, and the dose log is enough for the prescriber to decide whether to adjust, switch, or stop the medication.
